摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-4-恶唑甲醇 | 141567-53-5

中文名称
2-甲基-4-恶唑甲醇
中文别名
2-甲基恶唑-4-甲醇
英文名称
4-hydroxymethyl-2-methyloxazole
英文别名
(2-methyloxazol-4-yl)methanol;(2-methyl-1,3-oxazol-4-yl)methanol
2-甲基-4-恶唑甲醇化学式
CAS
141567-53-5
化学式
C5H7NO2
mdl
——
分子量
113.116
InChiKey
BGPDSEDYUPFTBI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    208.1±15.0℃ (760 Torr)
  • 密度:
    1.183±0.06 g/cm3 (20 ºC 760 Torr)
  • 闪点:
    79.6±20.4℃

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    8
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    46.3
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26
  • 危险类别码:
    R36
  • 海关编码:
    2934999090
  • 危险性防范说明:
    P305+P351+P338
  • 危险性描述:
    H319

SDS

SDS:f3315373339c43926dae14f2843c903b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: (2-Methyl-1,3-oxazol-4-yl)methanol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: (2-Methyl-1,3-oxazol-4-yl)methanol
CAS number: 141567-53-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H7NO2
Molecular weight: 113.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

2-甲基-4-恶唑甲醇是一种杂环有机化合物,可以通过丝氨酸甲酯盐酸盐作为起始原料制备得到。

用途

2-甲基-4-恶唑甲醇同样属于杂环有机物,可用作有机合成中间体。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-甲基-4-恶唑甲醇 在 chromium dichloride 、 草酰氯二甲基亚砜三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 87.0h, 生成 4-(4-iodo-2-methyl-buta-1,3-dienyl)-2-methyl-oxazole
    参考文献:
    名称:
    对映体全合成抗肿瘤大环内酯类RhizoxinD。
    摘要:
    描述了具有强大的抗肿瘤和抗真菌生物活性的天然产物-根瘤菌素D的聚合,高对映选择性合成。该分子的C(1)-C(9)片段是使用三倍拟对称中间体合成的,该中间体最终衍生自γ-丁内酯。通过手性拆分/不对称羟醛方案制备了根霉菌素D的中心核心。探索了产生多烯片段的几种方法,并最终从丝氨酸中分六个步骤制备了侧链。分子的左翼和右翼的统一是使用一步式烯烃化方案实现的,大环化是使用Horner-Emmons烯烃在C(2)-C(3)烯烃上进行的。
    DOI:
    10.1021/jo034011x
  • 作为产物:
    描述:
    2-甲基恶唑-4-羧酸二异丁基氢化铝 作用下, 以 正己烷二氯甲烷 为溶剂, 反应 3.0h, 以60%的产率得到2-甲基-4-恶唑甲醇
    参考文献:
    名称:
    Total Synthesis of Oxazole-Based Virginiamycin Antibiotics: 14,15-Anhydropristinamycin IIB
    摘要:
    DOI:
    10.1055/s-1998-5935
点击查看最新优质反应信息

文献信息

  • [EN] 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG<br/>[FR] DÉRIVÉS DE 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE EN TANT QU'INHIBITEURS DE LA PARG
    申请人:CANCER REC TECH LTD
    公开号:WO2016092326A1
    公开(公告)日:2016-06-16
    The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.
    本发明涉及作为PARG(Poly ADP-ribose glycohydrolase)酶活性抑制剂的I式化合物,其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c如本文所定义。本发明还涉及制备这些化合物的方法,包括含有它们的药物组合物,以及它们在治疗增殖性疾病(如癌症)以及其他涉及PARG活性的疾病或症状中的用途。
  • BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1186604A1
    公开(公告)日:2002-03-13
    Compounds of the general formula (I): or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R1 is a 5- to 6-membered aromatic ring which bears a substituent represented by the general formula: R-Z1-X-Z2- (wherein R1 is hydrogen or optionally substituted hydrocarbyl; X is optionally substituted alkylene; and Z1 and Z2 are each a heteroatom) and may be further substituted, with R being optionally bonded to the aromatic ring to form another ring; Y is optionally substituted imino; and R2 and R3 are each optionally substituted aliphatic hydrocarbyl or an optionally substituted hetero-alicyclic group.
    具有一般公式(I)的化合物: 或其盐,具有CCR5拮抗作用,并对HIV感染具有预防和治疗作用:其中R1是一个5至6成员的芳香环,带有一个由一般公式表示的取代基:R-Z1-X-Z2-(其中R1是氢或可选地取代的碳氢基;X是可选地取代的亚烷基;Z1和Z2都是杂原子)并可进一步取代,R可可选地与芳香环结合形成另一个环;Y是可选地取代的亚胺;R2和R3各自是可选地取代的脂肪族碳氢化合物或一个可选地取代的杂环脂肪族基团。
  • [EN] BICYCLIC COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF<br/>[FR] COMPOSES BICYCLIQUES INHIBANT L'ACTIVITE DE LA BETA-SECRETASE ET PROCEDES D'UTILISATION ASSOCIES
    申请人:ZAPAQ INC
    公开号:WO2006034277A1
    公开(公告)日:2006-03-30
    The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.
    本发明提供了双环β-分泌酶抑制剂及其用途,包括用于治疗阿尔茨海默病的方法。
  • SUBSTITUTED OXOPYRIDINE DERIVATIVES
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20170298052A1
    公开(公告)日:2017-10-19
    The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    这项发明涉及替代氧吡啶衍生物及其制备方法,以及将其用于生产治疗和/或预防疾病的药物,特别是心血管疾病,优选为血栓性或血栓栓塞性疾病,水肿,以及眼科疾病。
  • [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET LEURS MÉTHODES D'UTILISATION
    申请人:PRAXIS PREC MEDICINES INC
    公开号:WO2018148745A1
    公开(公告)日:2018-08-16
    The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
    本发明部分涉及融合的杂环基化合物和组合物,用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或症状,例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或症状的方法,包括德拉维特综合征或癫痫。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺